INMB Q4 2020 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11,000

Gross Profit

$11,000100.0% margin

Operating Income

-$3M-29172.7% margin

Net Income

-$3M-29127.3% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$702,938

Balance Sheet

Total Assets

$41M

Total Liabilities

$2M

Stockholders' Equity

$39M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11,000	$0	—
Gross Profit	$11,000	$0	—
Operating Income	-$3M	-$2M	-37.6%
Net Income	-$3M	-$2M	-38.2%